Go to the list of all blogs
John Y White's Avatar
published in Blogs
Oct 09, 2026
TickeronGET DAILY SIGNALS
ALGN vs VVOS: Align Technology's Stability Stands Out Against Vivos Therapeutics' -90% Slide

ALGN vs VVOS: Align Technology's Stability Stands Out Against Vivos Therapeutics' -90% Slide

Key Takeaways

  • ALGN is a large-cap, profitable medical device leader (Invisalign clear aligners and iTero scanners), while VVOS is a micro-cap, unprofitable sleep apnea device company in a strategic pivot.
  • The two names differ sharply in scale, with Align Technology near a $10 billion market value and Vivos Therapeutics around a low-single-digit million-dollar market capitalization.
  • Align generates roughly $4 billion in annual revenue with expanding margins; Vivos reported about $20.9 million in trailing revenue and a net loss of more than $25 million.
  • Relative performance has diverged: ALGN has pulled back modestly in recent weeks, while VVOS shares have fallen more than 90% over the past year amid dilution and listing concerns.
  • Align faces weakening consumer-demand signals in its imaging and systems business, while Vivos contends with balance-sheet repair and a Nasdaq minimum bid price compliance notice.

Setting the Scene

This comparison brings together two healthcare companies that operate in medical devices but could hardly be more different: Align Technology, with its established orthodontic and dental-imaging franchise, and Vivos Therapeutics, a small-cap player developing oral appliances for obstructive sleep apnea. Growth-oriented investors may appreciate Align's profitability and scale, while those comfortable with higher risk might see Vivos as a speculative turnaround play. Looking at recent market moves, performance trends, and the fundamentals underneath helps clarify where each sits and what the risk-reward balance looks like right now.

ALGN: Overview and Recent Moves

ALGN, Align Technology, designs and manufactures the Invisalign clear aligner system along with iTero intraoral scanners. In the latest quarter the company posted non-GAAP EPS of $2.64, up 6% from a year earlier, on revenue near $1.06 billion. Record Clear Aligner shipments and solid double-digit growth internationally helped drive the numbers, although the Imaging Systems and CAD/CAM Services segment slipped about 10.8% as capital-equipment demand softened and the mix shifted toward lower-priced options and leasing.

Sentiment has eased a bit lately. Evercore ISI moved the stock to In Line from Outperform and trimmed its price target, pointing to a softer consumer environment and slower demand indicators. Shares have eased roughly 9% over the past month, yet the consensus rating remains a Buy with an average target near $199. Management kept full-year revenue growth guidance at 3% to 4%, expanded its share-repurchase program, and entered a cooperation agreement with an activist investor. These steps point to a large-cap franchise that is stable yet growing more slowly as it navigates mixed signals from end markets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

VVOS: Overview and Recent Moves

VVOS, Vivos Therapeutics, develops and sells oral appliance therapies for obstructive sleep apnea, including its FDA-cleared CARE devices. The company is shifting its model away from enrolling independent dentists and toward owning and operating sleep testing and treatment centers, a move meant to boost revenue but one that demands sizable upfront spending.

The transition has pressured results so far. Second-quarter revenue climbed to about $5.15 million from $3.82 million a year earlier, yet the company still recorded a net loss. In the first quarter the net loss widened to $7.8 million, with cash around $2.1 million and a stockholders' equity deficit. Management has swapped outstanding debt for common shares to cut principal, and the company received a Nasdaq notice that its stock no longer meets the $1.00 minimum bid price requirement. Shares have dropped more than 90% over the past year and sit near their 52-week low, reflecting dilution and continued financing pressure, though the handful of covering analysts still carry a consensus price target well above the current level.

Side-by-Side Comparison

The most obvious difference between the two is financial staying power. Align Technology stays consistently profitable, holds more than $1 billion in cash, and finances its own growth and buybacks. Vivos Therapeutics remains unprofitable, runs with a thin cash position, and has leaned on debt-for-equity swaps and follow-on offerings to keep operations going. On the growth side, Align relies on wider global adoption of aligners plus momentum in teen and pediatric patients, while Vivos is counting on its integrated sleep-center network to expand OSA treatment reach.

Risk profiles also stand apart. Align's main concerns are macro-related, such as softer consumer spending and pricing pressure in scanners and certain international markets. Vivos faces more fundamental risks, including a sub-$1.00 share price, possible delisting, and ongoing shareholder dilution. Market views mirror the gap: Align draws broad institutional coverage and a Buy consensus, whereas Vivos sees thin coverage and extreme volatility. In short, Align delivers scale and steadiness with slower growth, while Vivos presents a speculative turnaround story with a much higher chance of capital loss.

AI-Assisted Perspective

From what I see in the data on trend consistency, financial stability, catalysts, and relative positioning, an AI-driven assessment would likely lean toward ALGN over VVOS in the current setting. Align shows a steadier trend structure, positive earnings, a solid balance sheet, and clear catalysts from upcoming results plus its capital-return program, even with some near-term demand softness. Vivos, on the other hand, carries higher volatility, continued dilution, and a weaker liquidity position that tends to lower confidence in trend-following models. This view is probabilistic, based on measurable traits today rather than any prediction of future returns.

Using Tickeron AI Trading Bots for Strategy Testing

When comparing names like these, I often review automated strategies through Tickeron’s marketplace of AI trading bots. The Trending AI Robots section surfaces bots whose recent signals, win rates, and consistency best match current conditions, offering a practical way to evaluate approaches across different risk profiles and timeframes without having to build everything from scratch.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ALGN, VVOS

Contributor

John Y White's AvatarJohn Y White|Beginner

Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active&section=trades&via=john


ALGN in -5.36% downward trend, falling for three consecutive days on November 20, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ALGN declined for three days, in 255 of 338 cases, the price declined further within the following month. The odds of a continued downward trend are 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ALGN moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 18 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALGN as a result. In 59 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.

The Moving Average Convergence Divergence Histogram (MACD) for ALGN turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 30 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

ALGN broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

ALGN moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ALGN crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.

Following a +9.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGN advanced for three days, in 187 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

The Aroon Indicator entered an Uptrend today. In 151 of 206 cases where ALGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ALGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.786) is normal, around the industry mean (4.964). P/E Ratio (28.769) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.611) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (2.612) is also within normal values, averaging (56.876).

The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -8%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 4%. STXS experienced the highest price growth at 12%, while RGNT experienced the biggest fall at -42%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 21%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 53
Price Growth Rating: 52
SMR Rating: 81
Profit Risk Rating: 94
Seasonality Score: 18 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of the invisalign system for treating malocclusion

Industry PharmaceuticalsOther

Industry
Medical Specialties
Address
410 North Scottsdale Road
Phone
+1 602 742-2000
Employees
20290
Web
https://www.aligntech.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.